FDA Approves Strensiq™ (asfotase alfa) for Treatment of Patients with Perinatal-, Infantile- and Juvenile-Onset Hypophosphatasia (HPP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Baird Remains Bullish on Alexion Pharma (ALXN) as FDA Approves Strensiq
October 27, 2015 9:14 AM EDTBaird reiterated an Outperform rating and $221.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following Strensiq's FDA approval for hypophosphatasia. The company plans to use a sales force approximately double that at Soliris launch, to promote both Strensiq and Kanuma (PDUFA: December 8) along with Medical... More
FDA Approves Strensiq for Alexion Pharma (ALXN); Oppenheimer Reiterates Outperform
October 26, 2015 3:25 PM EDTOppenheimer reiterated an Outperform rating and $228.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following FDA's approval of Strensiq for treatment of perinatal, infantile, and juvenileonset hypophosphatasia. Alexion announced anticipation of a $285,000 average annual cost initially for Strensiq. However, as children grow and live beyond HPP natural history,... More
Alexion Pharma (ALXN) to Resume Trading at 4:15 PM ET
October 23, 2015 3:57 PM EDTAlexion Pharma (NASDAQ: ALXN) to Resume Trading at 4:15 PM ET
... More